ReWalk Robotics has gained a major win with the Centers for Medicare & Medicaid Services' (CMS) decision to finalize a new rule covering exoskeleton technologies under Medicare braces benefits.

Earlier this year, CMS proposed defining "brace" to include powered exoskeletons like ReWalk's platforms for spinal cord injury patients. This week, the agency solidified that change which will take effect on January 1, 2024.

The move creates a clear coverage pathway for ReWalk's personal exoskeletons, allowing paralyzed users to stand and walk again. By categorizing them under brace benefits, CMS aims to expedite access and reimbursement through lump-sum Medicare payments.

Currently, obtaining coverage for such emerging assistive devices can be challenging. The new rule validation represents a shift in Medicare policy to enable access to life-changing innovation.

"Finalization of this rule is a major milestone in our efforts to expand access for the substantial proportion of the spinal cord injury community with Medicare coverage," said ReWalk CEO Larry Jasinski. "This is an important validation of the positive impact of exoskeletons."

Patient advocates and ReWalk have long lobbied for change around exoskeleton reimbursement policies that lagged behind technology advances. This decision brings Medicare in line with private insurers like Blue Cross Blue Shield that already cover ReWalk devices.

ReWalk expects the streamlined process to drive expanded utilization by making exoskeletons more affordable for eligible patients. The company sees growing demand as robotic technologies enable greater mobility and independence.

As a pioneer in personal exoskeletons, ReWalk is positioned to benefit tremendously from this regulatory shift. But the entire field can now accelerate development knowing critical coverage barriers have been removed, helping fulfill the promise of wearable robotics.